[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuritis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100635649","phase-2-dolutegravir-versus-dolutegravir-in-combination-with-tenofovir-for-the-treatment-of-htlv-1-infection-100635649",false,"NCT07555431","Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection","Dolutegravir Versus Dolutegravir in Combination With Tenofovir for the Treatment of HTLV-1 Infection (DOT-H): an Open-label, Randomized, Controlled Study.","DOT-H","Inclusion Criteria:\n\n* Age equal or higher than 18 years\n* Confirmed HTLV-1 infection\n* Clinical manifestation atributable to HTLV-1\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Active HIV, HCV (RNA+), or HBV (HBsAg+) infection\n* Active tuberculosis\n* Recent corticosteroid use\n* Renal impairment (CrCl \\\u003C50 mL\u002Fmin)\n* Autoimmune diseases\n* Wheelchair-bound individuals\n* Active malignancy (except ATLL)\n* Substance abuse interfering with adherence\n* Any condition compromising safety","ALL","18 Years",{"count":20,"type":21},146,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This phase 2b, open-label, randomized controlled trial evaluates the efficacy and safety of dolutegravir (DTG) alone versus dolutegravir combined with tenofovir disoproxil fumarate (TDF) in individuals with HTLV-1 infection and associated clinical manifestations. The primary objective is to compare changes in HTLV-1 proviral load at 24 and 48 weeks. Secondary outcomes include clinical, functional, immunological, and quality-of-life measures.",[27,28,29,30],"HTLV-1 Infection","HTLV I Associated Myelopathies","HTLV I Associated T Cell Leukemia Lymphoma","Neuritis",[32,33,34,35,36],"HTLV-1","Dolutegravir","Tenofovir","Treatment","proviral load","RECRUITING","2026-05-29",{"date":40,"type":41},"2026-06-02","ACTUAL",{"date":43,"type":41},"2026-05-07",{"date":45,"type":21},"2028-06",{"name":47,"class":48},"Carlos Brites","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":49},"100396963","resting-state-functional-mri-in-patients-with-optic-neuritis-for-anticipation-of-recovery-100396963","NCT04448938","RESting-state Functional MRI in Patients With Optic Neuritis for ANticipation of reCovEry","RESONANCE","Inclusion Criteria:\n\n* Patients over 18 years of age\n* Clinical suspicion of optic neuritis\n* Benefiting from an MRI for exploration of optic neuritis\n* Affiliate or beneficiary of a social security scheme\n* Having received informed information about the study and having given their express consent to participate in the study\n\nExclusion Criteria:\n\n* Contraindication to absolute or relative MRI (in particular, pregnant or breastfeeding women)\n* History of amblyopia\n* Any pre-existing pathology leading to a decrease in vision (e.g. retinitis pigmentosa, AMD, etc.)\n* Patient benefiting from a legal protection measure",{"count":58,"type":21},200,"OBSERVATIONAL","When patients arrive in the waiting room of the MRI department, patients will be given the briefing note explaining the purpose of the study and how it is going. During the consultation, the radiologist will check the inclusion and non-inclusion criteria, and will take the time to answer all of the patient's questions about the study. If the patient agrees to participate in the research, the investigating doctor will obtain his consent.\n\nThe MRI examination will be performed on a 3T multi-parametric MRI. Compared to the standard protocol, patients will benefit from an additional sequence of f-mRI, called resting state, and performed before injection of gadolinium contrast agent.\n\nA consultation with an ophthalmologist will also be carried out the same day, at the Adolphe de Rothschild Foundation. During this visit, an OCT examination (optical coherence tomography), a visual field as well as the measurement of visual acuity will be carried out, in accordance with the treatment usually practiced at the Adolphe de Rothschild Foundation.\n\nThe subjects of the control group who agreed to participate will benefit from an MRI examination which will include, in addition to the sequences planned for these patients according to their indications, the two non-injected sequences which will be performed on patients with suspected NO.\n\nThe possible existence of visual problems in the subjects of the control group will also be asked to them by interrogation. No eye exams or follow-up visits are planned, and control group participation will end after the MRI scan.\n\nPatients with NO will be seen in consultation by an ophthalmologist during a follow-up visit approximately 6 months after diagnosis. During this consultation, an OCT, a visual field and the measurement of visual acuity will be performed. This visit and the examinations carried out correspond to the usual care of patients suffering from NO and followed at the Adolphe de Rothschild Foundation Hospital.",[30],"2025-12-30",{"date":64,"type":41},"2026-01-05",{"date":66,"type":41},"2020-12-17",{"date":68,"type":21},"2027-06",{"name":70,"class":71},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK"]